PCR technologies market to reach USD 24.52B by 2030 

The PCR technologies market size is expected to reach USD 24.52 billion by 2030 from USD 13.10 billion in 2022 to record a CAGR of 8.2% from 2022 to 2030.

According to The Insight Partners study on the Global PCR Technologies Market is recording significant growth owing to the surging incidences of infectious diseases and genetic disorders.

Market segmentation

• Based on technology, the PCR technologies market is segmented into real-time PCR, conventional PCR, reverse transcription PCR, digital PCR, multiplex RT PCR, hot start PCR, and others. The real-time PCR segment held the largest market share in 2022.
• By offering, the PCR technologies market is segmented into reagents and consumables, instruments, and software and services. The reagents and consumables segment held the largest share of the market in 2022.
• In terms of application, the PCR technologies market is divided into gene expression analysis, genetic sequencing, genotyping, nucleic acid synthesis, standard validation, point-of-care diagnostics, environmental application, and others. The genetic sequencing segment held the largest share of the market in 2022.
• In terms of end user, the PCR technologies market is divided into hospitals and diagnostic centers, academia and research institutes, pharmaceutical and biotechnology companies, and others. The hospitals and diagnostic centers segment held a larger share of the PCR technologies market in 2022.
• The PCR technologies market is segmented into five major regions: North America, Europe, APAC, Middle East and Africa, and South and Central America.

Conclusion
Advancements in molecular biology, increased demand for rapid diagnostic solutions, and expanding applications of PCR technology in the healthcare research and environment sectors are accelerating growth and innovation in the PCR technology market. Digital PCR, multiplexing, and next-generation sequencing integration contribute to accuracy in genetic analysis. The acceptance of personalized medicine and point-of-care testing would fuel further expansion in the PCR technologies market. Moreover, automated systems and user-friendly software for primer design would automate the process, and make research and clinical use accessible to all. Stakeholders in the PCR technology marketplace plan to focus on all emerging trends and innovations to fully tap its potential to address modern-day scientific and medical problems. The report from The Insight Partners, therefore, provides several stakeholders—including component providers, system technology integrators, and system manufacturers—with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities.

PCR (Polymerase Chain Reaction) is a crucial tool in clinical settings due to its ability to amplify specific DNA and RNA sequences, enabling rapid and accurate detection of genetic variants, infectious diseases, and biomarkers. This molecular biology technique has revolutionized research, diagnostics, and various other applications. The increasing prevalence of chronic diseases and advancements in genomic research have further driven the demand for PCR-based diagnostics. As a result, PCR plays a key role in areas such as early detection of diseases, genetic testing, and the identification of pathogens.

Technological advancements in PCR, including automation, integration with software, and improvements in instruments and chemicals, have led to increased performance, sensitivity, and efficiency. These developments have made PCR workflows faster, more accurate, and cost-effective, contributing to the expanding market. Real-time PCR (qPCR) and portable systems, for example, have enhanced diagnostic capabilities, making PCR applicable in remote and point-of-care settings.

Overall, PCR’s continuous evolution and its diverse applications across healthcare, agriculture, and research have cemented its importance in modern molecular diagnostics.

Government and federal agencies worldwide recognize the role of quantitative polymerase chain reaction (qPCR) and dPCR products in genome-based research. In February 2019, Genome Canada partnered with the federal government of Canada and various provincial governments, companies, and research groups. Genome Canada received ~USD 42.6 million through these partnerships in funding for bioinformatics and human health genomics projects. Visby Medical, an infectious disease diagnostics company based in the US, obtained funding from the National Institutes of Health (NIH) in October 2020 for Phase 2 of its Rapid Acceleration of Diagnostics (RADx) initiative. The Insight Partners